Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sumitomo Dainippon

- PMLiVE

Chi-Med cues up two more regulatory filings in cancer

Hong Kong based firm reports strong sales in first marketed product

- PMLiVE

Biogen grows in Q2, but Spinraza performance a concern

Company banking on pipeline readouts and Tecfidra defence

- PMLiVE

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Strengthens existing relationship

- PMLiVE

Scancell preps phase 2 challenge for melanoma vaccine

Progress continues for biotech

- PMLiVE

UK financial authority confirms Woodford probe

Biotech investor in cross-hairs

- PMLiVE

Twentyeight-Seven raises another $15m for non-coding RNA drugs

Adds to funds raised from pharma venture units

- PMLiVE

Urovant slips on phase 3 incontinence drug data

Underwhelming results send shares down

Bluedog Launch Celebrations

Teams from all companies within the Lucid Group and Bluedog gathered to celebrate both the launch of this new partnership and Lucid Group’s twelve-year anniversary.  2019 is set to be a...

Lucid Group Communications Limited

Lucid Group brings creative and digital magic to the mix with the acquisition of Bluedog

Lucid Group is delighted to announce its first acquisition, welcoming colleagues from creative and digital consultancy Bluedog into its magic kingdom.Over the last twelve years, Lucid Group has become well...

Lucid Group Communications Limited

- PMLiVE

Alector kicks off next wave of biotech IPOs

US biotech raising money again

- PMLiVE

UK biotech booms in 2018, despite Brexit worries

Industry attracted a record-breaking £2.2bn in investment last year

- PMLiVE

Moderna CEO makes case for firm’s lofty valuation

mRNA specialist has to convince investors after stocks slide

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links